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Abstract 
P2X7, a damage-associated molecular pattern receptor and adenosine 5'-triphosphate (ATP)-gated cation 
channel, plays an important role in the activation of the NALP3 inflammasome and subsequent release of 
interleukin (IL)-1β from human monocytes; however its role in monocytes from other species including 
the dog remains poorly defined. This study investigated the role of P2X7 in canine monocytes, including 
its role in IL-1β release. A fixed-time flow cytometric assay demonstrated that activation of P2X7 by 
extracellular ATP induces the uptake of the organic cation, YO-PRO-12+, into peripheral blood monocytes 
from various dog breeds, a process impaired by the specific P2X7 antagonist, A438079. Moreover, in five 
different breeds, relative P2X7 function in monocytes was about half that of peripheral blood T cells but 
similar to that of peripheral blood B cells. Reverse transcription-PCR demonstrated the presence of P2X7, 
NALP3, caspase-1 and IL-1β in LPSprimed canine monocytes. Immunoblotting confirmed the presence of 
P2X7 in LPS-primed canine monocytes. Finally, extracellular ATP induced YO-PRO-12+ uptake into and 
IL-1β release from these cells, with both processes impaired by A438079. These results demonstrate that 
P2X7 activation induces the uptake of organic cations into and the release of IL-1β from canine 
monocytes. These findings indicate that P2X7 may play an important role in IL-1β-dependent processes 
in dogs. 
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Abstract 
P2X7, a damage-associated molecular pattern receptor and adenosine 5’-triphosphate (ATP)-
gated cation channel, plays an important role in the activation of the NALP3 in�lammasome 
and subsequent release of interleukin (IL)-1β from human monocytes, however its role in 
monocytes from other species including the dog remains poorly de�ined. This study 
investigated the role of P2X7 in canine monocytes, including its role in IL-1β release. A �ixed-
time �low cytometric assay demonstrated that activation of P2X7 by extracellular ATP induces 
the uptake of the organic cation, YO-PRO-12+, into peripheral blood monocytes from various 
dog breeds, a process impaired by the speci�ic P2X7 antagonist, A438079. Moreover, in �ive 
different breeds, relative P2X7 function in monocytes was about half that of peripheral blood 
T cells but similar to that of peripheral blood B cells. Reverse transcription-PCR demonstrated 
the presence of P2X7, NALP3, caspase-1 and IL-1β in LPS-primed canine monocytes. 
Immunoblotting con�irmed the presence of P2X7 in LPS-primed canine monocytes. Finally, 
extracellular ATP induced YO-PRO-12+ uptake into and IL-1β release from these cells, with 
both processes impaired by A438079. These results demonstrate that P2X7 activation induces 
the uptake of organic cations into and the release of IL-1β from canine monocytes. These 
�indings indicate that P2X7 may play an important role in IL-1β-dependent processes in dogs.
Keywords: damage-associated molecular pattern receptor; purinergic receptor; 
in�lammasome; interleukin-1β; monocyte; dog
Abbreviations: ATP, adenosine 5’-triphosphate; DAMP, damage-associated molecular 
pattern; MFI, mean �luorescence intensity; RT, reverse transcription.
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1. Introduction
Damage-associated molecular patterns (DAMPs) play important roles in in�lammation 
and immunity by functioning as signals of cell damage, stress or death during infection, injury 
or disease (Kono and Rock, 2008; Chen and Nuñez, 2010). One of the best-characterised 
DAMP is extracellular adenosine 5’-triphosphate (ATP), which mediates its effects through 
the activation of the P2X7 purinergic receptor, a trimeric ATP-gated cation channel (Bours, et 
al., 2011; Wiley, et al., 2011). Activation of P2X7 by extracellular ATP causes the �lux of Ca2+, 
Na+ and K+, as well as the uptake of organic cations such as ethidium+ and YO-PRO-12+ (Jarvis 
and Khakh, 2009). Furthermore, P2X7 activation induces various downstream events 
including the NALP3 in�lammasome-dependent maturation of IL-1β, and its subsequent 
release from various myeloid cell types (Di Virgilio, 2007). This event, at least in monocytes, 
requires the prior activation of cells with the TLR4 ligand, LPS, which results in the up-
regulation and assembly of the NALP3 in�lammasome, as well as the synthesis of IL-1β 
(Mehta, et al., 2001; Bauernfeind, et al., 2009). Due to this and other properties of P2X7 
activation, this receptor plays important roles in human health and disease (Sluyter and 
Stokes, 2011), and thus may have similar roles in canine health and disease.
The presence of functional P2X7 on human and murine cell types is well established, but 
little is known about P2X7 in other mammalian species including the dog. We have previously 
demonstrated that peripheral blood monocytes, lymphocytes and erythrocytes from English 
Springer Spaniels express functional P2X7 (Sluyter, et al., 2007; Shemon, et al., 2008; 
Stevenson, et al., 2009). In particular, we have previously shown that the relative amount of 
P2X7 function in monocytes is about half that of canine T cells but similar to that of B cells 
(Stevenson, et al., 2009). Similar studies in other dog breeds however are lacking, and given 
that distinct phenotypic traits exist between breeds it remains necessary to examine P2X7 in 
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additional breeds. Moreover, it remains unknown if P2X7 activation can induce the release of 
IL-1β from canine monocytes, and there is a general paucity of studies examining IL-1β 
release from canine myeloid cell types. Given the importance of P2X7 in human health and 
disease (Sluyter and Stokes, 2011), new knowledge about this receptor and events 
downstream of its activation in the dog is necessary to establish and understand the role of 
P2X7 in canine health and disease. Therefore, we investigated P2X7 in canine monocytes, and 
in particular its role in the release of IL-1β.
2. Materials and methods
2.1. Materials
Ficoll-PaqueTM PLUS was from GE Healthcare Biosciences (Uppsala, Sweden). A438079 
was from Tocris Bioscience (Ellisville, MO). ATP and LPS (Escherichia Coli serotype 055:B5) 
were from Sigma Chemical Co (St Louis, MO). YO-PRO®-1 iodide solution, RPMI-1640 
medium, L-glutamine and ExoSAP-IT were from Invitrogen (Grand Island, NJ). FCS was from 
Bovogen Biologicals (East Keilor, Australia). BigDye Terminator v3.1 was from Applied 
Biosystems (Carlsbad, CA).
2.2. Canine monocytes
Peripheral blood was collected into VACUETTE® lithium heparin tubes (Greiner Bio-
One, Frickenheisen, Germany) from either pedigree or cross breed dogs with informed, signed 
consent of pet owners, and with the approval of the University of Wollongong Ethics 
Committee (Wollongong, Australia). PBMCs were isolated from buffy coats using Ficoll-
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PaqueTM density centrifugation as described (Stevenson, et al., 2009). To study LPS-primed 
monocytes, PBMCs in complete culture medium (RPMI-1640 medium containing 2 mM L-
glutamine and 10% FCS) were incubated for 2 h at 37oC/5% CO2, the non-adherent cells were 
removed by gently washing twice with PBS, and the plastic-adherent cells incubated for a 
further 4 h in complete culture medium containing 100 ng/ml LPS. 
2.3. J774 cells
J774 cells (American Type Culture Collection, Rockville, MD), a murine macrophage 
cell line, were maintained in complete culture medium at 37oC/5% CO2.
2.4. Reverse transcription PCR
Total RNA was isolated using the RNeasy® Mini Kit (Qiagen, Hilden, Germany) 
according to the manufacturer's instructions. Reverse transcription (RT)-PCR was performed 
using Superscript® III One-Step RT-PCR System Platinum Taq DNA polymerase (Invitrogen) 
according to the manufacturer’s instructions using primer pairs (GeneWorks, Hindmarsh, 
Australia) speci�ic for P2X7, NALP3, caspase-1 or IL-1β mRNA transcripts (Table 1). The 
identity of each transcript was con�irmed by sequencing of Exo-SAP-IT puri�ied amplicons 
using the above primer pairs with BigDye Terminator and an Applied Biosystems 3130xl 
Genetic Analyzer.
2.5. Immunoblotting
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Immunoblotting of whole cell lysates was performed using a rabbit anti-rat P2X7 
polyclonal Ab (Alomone Labs, Jerusalem, Israel) as described (Constantinescu, et al., 2010). 
Immunoblotting demonstrated that this Ab binds a protein corresponding to the predicted 
size of glycosylated P2X7 in HEK-293 cells transfected with canine P2X7 cDNA but not in 
mock-transfected HEK-293 cells (Spildrejorde and Sluyter, unpublished results).
2.6. YO PRO 12+ uptake assay
ATP-induced YO-PRO-12+ uptake into PBMCs suspended in NaCl medium (145 mM 
NaCl, 5 mM KCl, 5 mM glucose, 0.1% BSA, 10 mM HEPES, pH 7.4) was determined using a 
�ixed-time �low cytometric assay as described (Gadeock, et al., 2010). To con�irm that ATP-
induced YO-PRO-12+ uptake was mediated by P2X7, cells were pre-incubated in the absence 
or presence of 10 μM A438079 for 15 min. Following ATP incubation, cells were then labelled 
with PerCP/Cy5.5- or allophycocyanin-conjugated anti-human/canine CD14 mAb (clone 
M5E2) (BioLegend, San Diego, CA). To assess YO-PRO-12+ uptake in lymphocytes, cells were 
labelled with murine anti-canine CD21-like (clone CA2.1D6) or CD3 (clone CA17.2A12) mAb 
(AbD Serotec, Oxford, United Kingdom), and allophycocyanin-conjugated donkey anti-murine 
IgG (eBioscience, San Diego, CA). Data was acquired using a LSR II �low cytometer (BD) and 
the mean �luorescence intensity (MFI) of YO-PRO-12+ uptake determined using FlowJo 
software (Tree Star, Ashland, OR).
2.7. IL 1β release assay
 ATP-induced IL-1β release from canine monocytes was performed as previously 
described for human monocytes (Sluyter, et al., 2004). Brie�ly, PBMCs in complete culture 
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medium were incubated in 24-well plates (0.625 x 106 cells/well) for 2 h at 37oC/5% CO2. 
Plates were washed and the plastic-adherent cells incubated for a further 4 h in complete 
culture medium containing 100 ng/ml LPS. The plastic-adherent cells were then pre-
incubated in the absence or presence of 50 μM A438079 in RPMI-1640 medium containing 
0.1% bovine serum albumin for 15 min, followed by incubation in the absence or presence of 
5 mM ATP (0.5 ml/well) for 30 min. Following ATP incubation, samples were centrifuged 
(11,000 x g for 30 s) and cell-free supernatants stored at -20oC until required. The amount of 
IL-1β in cell-free supernatants was quanti�ied using a Canine IL-1β VetSetTM ELISA 
Development Kit King�isher Biotech (St. Paul, MN) according to the manufacturer's 
instructions. 
2.8. Statistical analysis
Differences between treatments were compared using either the unpaired Student's t-
test or ANOVA (using Tukey's post test) for single or multiple comparisons, respectively. 
Errors are expressed as SDs.
3. Results and discussion
3.1. P2X7 activation induces organic cation uptake into peripheral blood monocytes 
To determine if P2X7 activation induces the uptake of an organic cation into 
monocytes from additional dog breeds to English Springer Spaniels, ATP-induced YO-PRO-12+ 
(375 Da) uptake into peripheral blood monocytes from two Staffordshire Bull Terriers and 
one Bull Terrier was examined in the absence or presence of A438079, which impairs human, 
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monkey, rat and murine P2X7 (Donnelly-Roberts, et al., 2009; Bradley, et al., 2011). In the 
absence of A438079, ATP induced YO-PRO-12+ uptake into peripheral blood monocytes from 
all three dogs (Fig. 1A). Pre-incubation with this antagonist impaired ATP-induced YO-PRO-
12+ uptake by 93 ± 13% (Fig. 1A). Thus, P2X7 activation induces the uptake of YO-PRO-12+ 
into canine peripheral blood monocytes, and the presence of functional P2X7 receptors on 
peripheral blood monocytes is not restricted to one breed.
To determine the relative pattern of P2X7 function in leukocytes from various dog 
breeds other than English Springer Spaniels, ATP-induced YO-PRO-12+ uptake into peripheral 
blood monocytes from �ive different breeds was examined. As above (Fig. 1A), ATP induced 
YO-PRO-12+ uptake into peripheral blood monocytes from each dog (Fig. 1B). ATP also 
induced YO-PRO-12+ uptake into peripheral blood B and T cells from each dog, with the 
average amount of uptake three-fold greater in T cells compared to monocytes and B cells 
(range fold increase of 2.7-4.5 and 1.7-3.8, respectively) (Fig. 1B). Thus, a relative pattern of 
P2X7 function similar to that observed for English Springer Spaniels (Stevenson, et al., 2009) 
is also seen between peripheral blood monocytes, B cells and T cells from �ive other dog 
breeds (Australian Bulldog, Border Collie, Bull Terrier, Jack Russell Terrier and Staffordshire 
Bull Terrier). The difference between canine monocytes, B cells and T cells most likely relates 
to the amount of P2X7 expression, as cell-surface P2X7 expression correlates with P2X7 
function in human leukocytes (Gu, et al., 2000). Moreover, the consistent pattern of P2X7 
function between leukocyte subsets from the various breeds suggests that the regulation of 
P2X7 expression is highly conserved within dogs. The pattern of P2X7 function between 
leukocyte subsets from humans is also similar however, in contrast to dogs, P2X7 function is 
�ive-fold higher in human peripheral blood monocytes compared to human peripheral blood B 
or T cells (Gu, et al., 2000; Stevenson, et al., 2009). Whether these differences between the two 
species are of physiological signi�icance remain unknown. Nevertheless, despite these species 
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dissimilarities, it appears likely that functional P2X7 receptors are expressed on peripheral 
blood monocytes, B cells and T cells from all dog breeds.
3.2 P2X7 activation induces organic cation uptake into and IL 1β release from LPS
primed monocytes 
To determine if P2X7 can induce the release of IL-1β from canine monocytes, the 
presence of mRNA transcripts for P2X7 and IL-1β, as well as for the NALP3 in�lammasome 
components, NALP3 and caspase-1, were examined in LPS-primed canine monocytes. RT-PCR 
demonstrated the presence of mRNA transcripts for all four molecules (Fig. 2A), with 
transcripts corresponding to the predicted size (Table 1) for each molecule (results not 
shown). Moreover, with the exception of IL-1β (due to its small size of 64 bp), the identity of 
each transcript was con�irmed by sequencing (results not shown). No PCR products were 
observed in the water control (Fig. 2A).
To determine if LPS-primed canine monocytes express functional P2X7, the presence 
of P2X7 protein was examined by immunoblotting. Murine J774 macrophages, which express 
P2X7 (Coutinho-Silva, et al., 2005), were used as a positive control. Immunoblotting with an 
anti-P2X7 Ab demonstrated the presence of a major band at 75 kDa, the predicted size of 
glycosylated P2X7, in both cell types (Fig. 2B). Minor bands were also observed at 60 and 68 
kDa in LPS-primed canine monocytes and J774 cells, respectively (Fig. 2B). These minor 
bands most likely represent a degradation product and non-glycosylated P2X7, respectively.
To con�irm that P2X7 was functional in LPS-primed canine monocytes, ATP-induced 
YO-PRO-12+ uptake was examined in the absence or presence of A438079. In the absence of 
A438079, ATP induced YO-PRO-12+ uptake into LPS-primed canine monocytes (Fig. 2C). Pre-
incubation with this antagonist impaired ATP-induced YO-PRO-12+ uptake by 97 ± 4% (Fig. 
Page 10 of 19
10
2C). A438079 in the absence of ATP had no signi�icant effect on YO-PRO-12+ uptake compared 
to YO-PRO-12+ uptake in the absence of both A438079 and ATP (results not shown). Thus, 
LPS-primed canine monocytes from two pure breeds (Australian Kelpie and two Labradors) 
and from one cross breed (Border Collie cross Australian Cattle Dog) express functional P2X7 
receptors.
Finally, to determine if P2X7 activation induces IL-1β release from LPS-primed canine 
monocytes, cells were pre-incubated in the absence or presence of A438079 prior to 
incubation in the absence or presence of ATP, and the amount of IL-1β in cell-free 
supernatants measured using a canine IL-1β ELISA. In the absence of A438079, ATP induced 
IL-1β release from LPS-primed canine monocytes (Fig. 2D). Pre-incubation with this 
antagonist impaired ATP-induced IL-1β release by 97 ± 9% (Fig. 2D). A438079 in the absence 
of ATP had no signi�icant effect on IL-1β release compared to IL-1β release in the absence of 
both A438079 and ATP (results not shown). Thus, P2X7 activation induces the release of IL-
1β from LPS-primed canine monocytes. To the best of our knowledge, the P2X7-induced IL-1β 
release from canine monocytes has not been previously reported, however others, using 
peripheral blood from Beagles, have shown that P2X7 activation induces IL-1β release in a 
whole-blood assay (Roman, et al., 2009). Collectively, these observations are consistent with 
�indings with human monocytes or whole blood (Perregaux, et al., 2000; Mehta, et al., 2001; 
Sluyter, et al., 2004; Bauernfeind, et al., 2009), and indicate that P2X7 may also play an 
important role in IL-1β-dependent processes in dogs.
3.3. P2X7 and the NALP3 in�lammasome in canine health and disease 
P2X7 has an established role in in�lammation and immunity (Bours, et al., 2011; Wiley, 
et al., 2011), and related disorders that include in�lammatory arthritis, and neuropathic and 
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in�lammatory pain (Labasi, et al., 2002; Chessell, et al., 2005). The action of P2X7 in these 
circumstances is largely attributed to its release of IL-1β from monocytes and macrophages, 
although other in�lammatory mediators may also be involved (Hughes, et al., 2007). 
Nonetheless, P2X7 is attracting considerable interest as a therapeutic target in humans 
(Donnelly-Roberts and Jarvis, 2007; Arulkumaran, et al., 2011), and it is likely that 
compounds that target P2X7 will have similar therapeutic bene�its in dogs. The results also 
support the use of the dog as a suitable model to study the role of P2X7 in health and disease, 
as well as to test the therapeutic ef�icacy and other pharmacological parameters of P2X7 
antagonists before commencing human clinical trials. In regard to this latter point, dogs have 
been used to test the bioavailability and half-life of potential P2X7 antagonists for use as 
therapeutics in humans (Abberley, et al., 2010; Duplantier, et al., 2011).
3.4. Conclusion 
The current study demonstrates that functional P2X7 receptors are present in 
peripheral blood monocytes from various breeds, and that the relative P2X7 function in these 
cells is about half that of peripheral T cells but similar to that of peripheral blood B cells. 
Moreover, the study demonstrates that LPS-primed canine monocytes produce mRNA 
transcripts for P2X7 and IL-1β, as well as for the NALP3 in�lammasome components, NALP3 
and caspase-1. Finally, the study demonstrates that these cells express P2X7 protein, and that 
activation of this receptor induces the uptake of the organic cation, YO-PRO-12+, and the 
release of IL-1β. Collectively, these results show that dogs express functional P2X7 receptors, 
and that this receptor may play important roles in canine health and disease, and thus may 
represent a promising therapeutic target in dogs.
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Figure legends
Fig. 1. P2X7 activation induces organic cation uptake into peripheral blood monocytes. (A) 
Canine PBMCs (from a Bull Terrier or two Staffordshire Bull Terriers) in NaCl medium were 
pre-incubated in the absence (Control) or presence of 10 μM A438079 at 37oC for 15 min. 
PBMCs were then incubated with 1 μM YO-PRO-12+ in the absence or presence of 1 mM ATP at 
37oC for 5 min. (B) Canine PBMCs (from various breeds as indicated) in NaCl medium 
containing 1 μM YO-PRO-12+ were incubated in the absence or presence of 1 mM ATP at 37oC 
for 5 min. (A,B) Incubations were stopped by MgCl2 solution and centrifugation, the PBMCs 
labelled with (A,B) anti-CD14 mAb, or (B) anti-CD21-like or anti-CD3 mAb, and the MFI of YO-
PRO-12+ uptake into monocytes, B cells and T cells, respectively measured by �low cytometry. 
ATP-induced YO-PRO-12+ uptake was de�ined as the difference in the MFI of YO-PRO-12+ 
uptake in the presence and absence of ATP for each group. Symbols represent individual dogs; 
bars represent group mean; **P<0.01, ***P<0.001 compared to (A) Control or (B) monocytes 
or B cells. 
Fig. 2. P2X7 activation induces organic cation uptake into and IL-1β release from LPS-primed 
monocytes. (A-D) Adherent PBMCs (from various breeds or cross breeds) in complete 
medium containing 100 ng/ml LPS were incubated at 37oC for 4 h. (A) Isolated RNA from LPS-
primed monocytes was ampli�ied by RT-PCR using primers speci�ic for various mRNA 
transcripts (as indicated) and the products examined by agarose gel electrophoresis. H2O in 
place of RNA was used as a negative control. (B) Whole lysates of LPS-primed monocytes 
(Mon) or J774 cells were separated by SDS-PAGE, transferred to nitrocellulose membrane and 
probed with anti-P2X7 Ab. (C) LPS-primed monocytes in NaCl medium were pre-incubated in 
the absence (Control) or presence of 10 μM A438079 at 37oC for 15 min. Monocytes were 
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then incubated with 1 μM YO-PRO-12+ in the absence or presence of 1 mM ATP at 37oC for 5 
min. Incubations were stopped by MgCl2 solution and centrifugation, the monocytes labelled 
with anti-CD14 mAb, and the MFI of YO-PRO-12+ uptake measured by �low cytometry. ATP-
induced YO-PRO-12+ uptake was de�ined as the difference in the MFI of YO-PRO-12+ uptake in 
the presence and absence of ATP. (D) LPS-primed monocytes in RPMI-1640 medium 
containing were pre-incubated in the absence (Control) or presence of 50 μM A438079 at 
37oC for 15 min, followed by incubation in the absence or presence of 5 mM ATP for 30 min. 
The amount of IL-1β in cell-free supernatants was quanti�ied using an IL-1β ELISA. ATP-
induced IL-1β release was de�ined as difference in IL-1β concentration in the presence and 
absence of ATP. (C,D) Symbols represent individual dogs; bars represent group mean; 






































aPrimers  were  designed  for  mRNA  transcripts  of  P2X7,  NALP3  and  caspase‐1  from  the 
sequences,  NM_001113456.1,  XM_843284.2  and  NM_001003125.1,  respectively 
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Figure 2
